Xin Lang Cai Jing·2025-09-03 07:58Core Viewpoint - The company, WuXi AppTec, is a leading global provider of integrated new drug research and production services, benefiting from the depreciation of the Renminbi and its strong position in the CRO and CMO sectors [2][3]. Company Overview - WuXi AppTec is an integrated platform for the discovery, development, and production of small molecule chemical drugs, serving global pharmaceutical companies [2][7]. - The company was established on December 1, 2000, and went public on May 8, 2018 [7]. - The revenue composition includes: Chemical business 78.37%, Testing business 12.93%, Biological business 6.02%, Other (supplement) 1.90%, Other business 0.79% [7]. Financial Performance - For the first half of 2025, WuXi AppTec achieved revenue of 20.799 billion yuan, a year-on-year increase of 20.64%, and a net profit attributable to shareholders of 8.561 billion yuan, up 101.92% year-on-year [7]. - The company has distributed a total of 13.027 billion yuan in dividends since its A-share listing, with 9.373 billion yuan distributed over the past three years [8]. Market Position - WuXi AppTec holds a dominant position in the domestic pharmaceutical outsourcing industry and is one of the earliest companies engaged in CRO and CMO services in China [2]. - As of the 2024 annual report, overseas revenue accounted for 78.67% of total revenue, benefiting from the depreciation of the Renminbi [3]. Shareholder Information - As of July 15, 2025, the number of shareholders is 235,500, with no change in the average circulating shares per person [7]. - Major shareholders include Hong Kong Central Clearing Limited and various ETFs, with notable increases in holdings by some institutional investors [8][9].